<?xml version="1.0" encoding="UTF-8"?>
<ref id="B15-vaccines-08-00306">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Paavonen</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Jenkins</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Bosch</surname>
    <given-names>F.X.</given-names>
   </name>
   <name>
    <surname>Naud</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Salmeron</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Wheeler</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Chow</surname>
    <given-names>S.N.</given-names>
   </name>
   <name>
    <surname>Apter</surname>
    <given-names>D.L.</given-names>
   </name>
   <name>
    <surname>Kitchener</surname>
    <given-names>H.C.</given-names>
   </name>
   <name>
    <surname>Castellsague</surname>
    <given-names>X.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Efficacy of a prophylactic adjuvanted bivalent l1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase iii double-blind, randomised controlled trial</article-title>
  <source>Lancet</source>
  <year>2007</year>
  <volume>369</volume>
  <fpage>2161</fpage>
  <lpage>2170</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60946-5</pub-id>
  <pub-id pub-id-type="pmid">17602732</pub-id>
 </element-citation>
</ref>
